Document is current
Any future updates will be listed below
-
Authors
de-la-Rosa-Gay, Cristina https://orcid.org/0009-0004-1518-8648
Valmaseda-de-la-Rosa, Sofia https://orcid.org/0009-0002-9608-081X
Hernández-Mangas, Andrea https://orcid.org/0009-0001-5656-4193
Camps-Font, Octavi https://orcid.org/0000-0001-9991-2226
Valmaseda-Castellón, Eduard https://orcid.org/0000-0001-9669-3187
Figueiredo, Rui https://orcid.org/0000-0002-2122-6530
-
Funding
Funding for this research was provided by:
Fundació Institució dels Centres de Recerca de Catalunya
- License Information
-
More Information
Article History
Received: 7 January 2026
Accepted: 5 May 2026
First Online: 13 May 2026
Declarations
:
: Cristina de-la-Rosa-Gay, Sofia Valmaseda-de-la-Rosa and Andrea Hernández-Mangas declare no conflicts of interest.• Eduard Valmaseda-Castellón, Rui Figueiredo, and Octavi Camps-Font report grants, personal fees, and non-financial support from Avinent (Spain), Inibsa (Spain), Dentaid SL (Spain). Dr. Valmaseda-Castellón and Rui Figueiredo also report grants and personal fees from MozoGrau (Spain) and personal fees from Laboratorios Silanes (Mexico) outside the submitted work. They have also participated as investigators in randomized clinical trials sponsored by Geistlich Pharma AG (Switzerland), Mundipharma (UK), Hyloris Development (Belgium) and BBraun (Germany). Dr. Rui Figueiredo and Octavi Camps-Font also reports personal fees from Nobel Biocare (Switzerland). Dr. Figueiredo additionally reports personal fees from Geistlich Pharma AG and Septodont (France).
